Azeliragon
As of the edition of 20 October 2026, Azeliragon is a small molecule: stopped in 2026; acts on AGER.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 16, 4 stopped early
- Disease areas
- Cancer; Nervous system; Mental health; Digestive system; Hormones; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Azeliragon.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AGER | Advanced glycation end product-specific receptor | Q15109 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 0 | 2 | 1 |
| Phase 2 | 10 | 3 | 4 | 1 |
| Phase 3 | 3 | 0 | 1 | 2 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2005 to now |
| vTv Therapeutics | Lead sponsor of trials | 2015 to now |
| Cantex Pharmaceuticals | Lead sponsor of trials | 2023 to now |